



First Quarter 2021 Financial Results Presentation

May 5, 2021

Forward-Looking Statements

In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2021) and expectations for profitability, revenue (including expectations for future milestones and royalty growth), operating income, expenses and earnings-per-share and the Company's plans to continue its share repurchase program and to potentially expand its platform through acquisitions. Forward-looking statements regarding the Company's ENHANZE® drug delivery technology may include the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery of injectable medications through subcutaneous delivery. Forward-looking statements regarding the Company's ENHANZE® business may include potential growth driven by our partners' development and commercialization efforts (including anticipated new clinical trial starts and ENHANZE® product launches), projections for future sales revenue of our collaborators' products, potential new ENHANZE® collaborations and collaborative targets and potential approvals of new ENHANZE® products. These forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues (including royalty and milestone revenue received from our collaboration partners), expenditures and costs, unexpected delays in the execution of the Company's share repurchase program or planned platform expansion, unexpected results or delays in the growth of the Company's ENHANZE® business, or in the development, regulatory review or commercialization of ENHANZE® products, including any potential delays caused by the current COVID-19 global pandemic, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's most recently filed Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.

Non-GAAP Financial Measures:


In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), these materials contain certain non-GAAP financial measures. The Company reports non-GAAP net income and non-GAAP diluted earnings per share and expectations of those measures in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Reconciliations between GAAP and non-GAAP financial measures are included in these materials.

Note: This presentation contains product names, trademarks and registered trademarks are property of their respective owners


Continued Strong Royalty Growth Primarily Driven by DARZALEX[®] (daratumumab) SC Launch

Quarterly Royalty Revenue (\$M)

119% year-over-year growth and **15%** sequential growth in Q1 2021 driven by DARZALEX[®] SC utilizing ENHANZE[®]



Annual Royalty Revenue (\$M)



Five Partner Products Commercialized in Global Markets: Wave 1 and 2 Launches

Wave 1

HyQvia
[Immune Globulin Infusion 10% (Human)
with Recombinant Human Hyaluronidase]

RituxanHYCELA™
rituximab/hyaluronidase human
subcutaneous injection | 1,400 mg/23,400 Units
1,600 mg/26,800 Units

MabThera SC
Rituximab Subcutaneous
FAST • EASY • EFFECTIVE

Herceptin HYLECTA™
trastuzumab and hyaluronidase-oysk
INJECTION FOR SUBCUTANEOUS USE | 600 mg/10,000 units

Herceptin SC
trastuzumab
subcutaneous

Wave 2

DARZALEX Faspro™
(daratumumab and hyaluronidase-fihj)
Injection for subcutaneous use | 1,800mg/30,000units

DARZALEX® SC

PHESGO™
pertuzumab/trastuzumab/hyaluronidase-zzxf
SUBCUTANEOUS INJECTION | 1,200 mg/600 mg/30,000 units
600 mg/600 mg/20,000 units

Project 16 Products In Development by YE 2021

Current Program / Product	Indications	Phase 1 New Starts	Phase 1 Ongoing	Phase 2 Trial Starts	Phase 3 Trial Starts
Teprotumumab-trbw (Horizon)	Thyroid Eye Disease		New in Q1		
N6LS bnAb (VRC)	HIV (treatment)		New in Q1		
ARGX-117 (argenx)	Multifocal motor neuropathy				
Anti-TIM3 (BMS)	Solid tumors				
Amivantamab (Janssen)	Solid tumors				
CAP256V2LS (CAPRISA)	HIV (vaccine)				
Nivolumab (BMS)	Solid tumors				
Anti-CD73 (BMS)	Solid tumors				
Nivolumab+Relatlimab (BMS)	Solid tumors				
Ocrelizumab (Roche)	Multiple sclerosis				
Undisclosed (Alexion)	Undisclosed				
Atezolizumab (Roche)	NSCLC				
Efgartigimod (argenx)	CIDP				New in Q1
Efgartigimod (argenx)	Immune thrombocytopenia				
Efgartigimod (argenx)	Pemphigus vulgaris				New in Q1
Efgartigimod (argenx)	MG				

Total of Five New Products Expected to Enter Clinic in 2021

Projected Milestones Drive Revenue and Free Cash Flow

3 Year Forward Milestone Revenue Projection



Includes development, commercial and new agreement upfront milestones

Continue to Return Significant Capital to Shareholders

Capital Allocation Priorities

1 Maintain Strong Balance Sheet

- Cash & cash equivalents \$764M at March 31, 2021
- Convertible debt, net \$874M
 - \$805M 2027 notes, re-purchased 80% of \$460M principal 2024 notes

2 Share Repurchases

- \$550M repurchase program 2019-2022
- \$426M completed to date at an average price of \$21.99
- \$76M repurchased in Q1 w/ \$49M remaining in 2021

3 Internal and External Growth

- Continue to fund ENHANZE®
- Potential M&A expanding platform technologies

First Quarter 2021 Revenue Highlights¹

\$ U.S. in Millions (unaudited)

	Q1 2021	Q1 2020	% Change
Total Revenue	\$89.0	\$25.4	--
Royalty Revenue	\$36.9	\$16.8	119%
Product Sales (incl. bulk rHuPH20 and ENHANZE [®] Drug Product Sales, and Hylenex [®] (Hyaluronidase Human Injection))	\$21.8	\$8.1	167%
Collaboration Revenue	\$30.3	\$0.4	--

1) Dollar amounts and percentages, as presented, are rounded. Consequently totals may not add up.

First Quarter 2021 Financial Highlights¹

\$ U.S. in Millions, except EPS (unaudited)

	Q1 2021	Q1 2020	% Change
Total Revenue	\$89.0	\$25.4	--
Total Operating Expense	\$38.3	\$28.6	34%
Cost of Product Sales	\$18.2	\$5.8	--
R&D Expense	\$9.0	\$10.2	(11%)
SG&A Expense	\$11.1	\$12.6	(12%)
Operating Income	\$50.7	(\$3.2)	--
Net Income / (Loss)	\$27.9	(\$6.1)	--
GAAP Diluted Earnings per Share	\$0.19	(\$0.04)	--
Non-GAAP Diluted Earnings per share	\$0.37	\$0.02	--

2021 Financial Guidance

	2021	Comment
Net Revenue	\$375 - \$395M	<ul style="list-style-type: none"> - Guidance is unchanged and represents growth of 40% to 48%. - Revenues from royalties projected to double - Product sales projected to increase 50-60% driven by bulk API orders - Revenues under collaborative agreements in a similar range as 2020
Operating Income	\$215 - \$235M	<ul style="list-style-type: none"> - Guidance is unchanged and represents growth of 49% to 63% - Increase in COGS commensurate with percentage increase in projected product sales - Expect operating expense excluding COGS \$80-\$83M
GAAP Net Income	\$190 - \$210M	
Non-GAAP Net Income	\$235 - \$255M	<ul style="list-style-type: none"> - Excludes: one-time inducement expense related to convertible note, stock-based compensation, amortization of debt issuance/discount and the related income tax effect
GAAP Diluted EPS	\$1.25 - \$1.40	
Non-GAAP Diluted EPS	\$1.55 - \$1.70	<ul style="list-style-type: none"> - Excludes: one-time inducement expense related to convertible note, stock-based compensation, amortization of debt issuance/discount and the related income tax effect

Potential Value-Driving Events in 2021

- Continued product launch momentum (Wave 2):
 - DARZALEX® SC: US and International
 - Phesgo® US and EU Launch
- 4 products in Phase 3 in 7 Indications: Potential Wave 3 launches
- 5 NEW phase 1 starts resulting in 12 ongoing Phase 1: Potential Wave 4 launches
- New partners, new nominations/trial starts: Potential Wave 5 launches
- Opportunity to return capital to shareholders through continued share repurchases and potential M&A





Q1 2021 Financial Results Appendix

GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS

\$ U.S. in thousands, except per share amounts (unaudited)¹

	Three Months Ended March 31,	
	2021	2020
GAAP Net Income (Loss)	\$ 27,895	\$ (6,103)
Adjustments:		
Inducement expense related to convertible note	20,960	—
Share-based compensation	4,923	4,531
Amortization of debt discount	741	3,478
Income tax effect of above adjustments	(181)	15
Non-GAAP Net Income (Loss)	\$ 54,338	\$ 1,921
GAAP Diluted EPS	\$ 0.19	\$ (0.04)
Adjustments:		
Inducement expense related to convertible note	0.14	—
Share-based compensation	0.03	0.03
Amortization of debt discount	0.01	0.03
Income tax effect of above adjustments	—	—
Non-GAAP Diluted EPS	\$ 0.37	\$ 0.02
GAAP & Non-GAAP Diluted Shares	148,540	137,186

GAAP to Non-GAAP Reconciliation: Net Income and Diluted EPS 2021 Guidance

\$ U.S. in Millions, except EPS (unaudited)¹

	2021	2020
GAAP Net Income (Loss)	\$ 190 - 210	\$ 129.1
Adjustments:		
Inducement expense related to convertible note	21 - 21	—
Share-based compensation	21 - 22	17.2
Amortization of debt discount	4 - 4	14.1
Non-GAAP Net Income (Loss)	\$ 235 - 255	\$ 160.4
GAAP Diluted EPS	\$ 1.25 - 1.40	\$ 0.91
Adjustments:		
Inducement expense related to convertible note	0.14 - 0.14	—
Share-based compensation	0.14 - 0.15	0.12
Amortization of debt discount	0.02 - 0.02	0.10
Non-GAAP Diluted EPS	\$ 1.55 - 1.70	\$ 1.12
GAAP & Non-GAAP Diluted Shares	149 - 150	141.5